3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
30
Carcinoma, Renal Cell
11
Neoplasms
6
Neoplasm Metastasis
6
Recurrence
4
Multiple Myeloma
4
Carcinoma, Hepatocellular
4
Leukemia
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neuroendocrine Tumors
2
Mycosis Fungoides
2
Lymphoma, Follicular
2
Lymphoma
2
Liver Neoplasms
2
Kidney Neoplasms
2
Hematologic Neoplasms
2
Breast Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Amifostine
19
Cisplatin
15
Radiotherapy
13
Etoposide
10
Cyclophosphamide
9
Carboplatin
8
Paclitaxel
7
Filgrastim
7
Drug Therapy
5
Cytarabine
5
apatinib
4
sodium thiosulfate
3
Methylprednisolone
3
Methotrexate
3
Gemcitabine
3
Docetaxel
3
sargramostim
2
pegfilgrastim
2
etoposide phosphate
2
camrelizumab
2
Vincristine
2
Pyridoxine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mitoxantrone
2
Melphalan
2
Irinotecan
2
Ifosfamide
2
Fibroblast Growth Factor 7
2
Epoetin Alfa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Drug-Related Side Effects and Adverse Reactions
×
Introns
×
Clear all
NCT00221702
2010-10-13
EADO
University Hospital, Bordeaux
Phase 3
Completed
898 enrolled